SinoMab Narrows Loss as Key Antibody Programs Advance and Funding Base Expands

SinoMab Bioscience Ltd. ( (HK:3681) ) just unveiled an update.

SinoMab reported notable clinical and R&D progress in 2025, led by its key asset SM17, a first-in-class humanised monoclonal antibody against the IL-25 receptor, which delivered positive Phase 1b topline results in moderate-to-severe atopic dermatitis by showing dual benefits in itch relief and skin healing. The company also initiated a Phase 1 subcutaneous bridging study in healthy volunteers and secured Chinese regulatory approval to begin clinical development of SM17 in inflammatory bowel disease, broadening its potential indications.

The group’s flagship antibody SM03 (Suciraslimab), an anti-CD22 biologic, generated encouraging preclinical data in systemic lupus erythematosus, suggesting benefits in proteinuria and possible lupus nephritis through a differentiated, non–B-cell-depleting mechanism that may offer organ protection. SinoMab further strengthened its innovation capabilities via a strategic collaboration with Sun Yat-sen University Institute of Advanced Studies Hong Kong and bolstered its balance sheet with two share subscriptions that expanded available funding to RMB351.5 million, while narrowing its annual loss as spending shifted from large-scale trials to earlier-stage studies.

The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.

More about SinoMab Bioscience Ltd.

SinoMab BioScience Limited is a Hong Kong–incorporated biopharmaceutical company focused on the research, development, production and commercialisation of novel monoclonal antibody drugs for immunological diseases. Its pipeline targets conditions such as atopic dermatitis, inflammatory bowel disease and systemic lupus erythematosus, positioning the group in the global market for innovative autoimmune therapies.

Average Trading Volume: 5,121,453

Technical Sentiment Signal: Hold

Current Market Cap: HK$2.32B

See more data about 3681 stock on TipRanks’ Stock Analysis page.